A translational study investigating the potential bypass mechanisms to PI3K/mTOR inhibition in KRAS mutant CRC revealed the enhancement of other signaling pathways like EGFR, ERBB2, and ERBB3 as mechanisms of resistance, suggesting that combined PI3K/mTOR and EGFR inhibitors may improve therapeutic outcomes [62]. This evidence concerns the gene KRAS and colorectal carcinoma.